Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Iterum Therapeutics plc Director's Dealing 2021

Jun 25, 2021

34796_dirs_2021-06-25_c6d1b575-a7d0-4e54-8a1c-0a78a986ebe4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2021-06-23

Reporting Person: Kelly David George (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-23 Stock Option (Right to Buy) $2.01 A 64706 Acquired 2031-06-22 Ordinary Shares (64706) Direct

Footnotes

F1: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the shares subject to this option shall vest in full on June 23, 2022.